| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Ipratropium Bromide, as short‐acting anticholinergic, is indicated for the maintenance treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), including chronic bronchitis and emphysema[3]. Both IB (Ipratropium Bromide) and AS (Albuterol Sulfate) elicit significant bronchodilation, although the magnitude of the bronchodilator response is greater following IB[4]. Moreover, routine nebulized ipratropium bromide premedication for bronchoscopy could be useful and beneficial[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03405090 | Chronic Obstructive Pulmonary ... 展开 >>Disease 收起 << | Phase 4 | Recruiting | August 2019 | Canada, Ontario ... 展开 >> Respiratory Investigation Unit Recruiting Kingston, Ontario, Canada, K7L 2V7 Contact: Megha Ibrahim Masthan, MSc 613-549-6666 ext 4314 mim5@queensu.ca Contact: Sandra Vincent 613-549-6666 ext 4890 vincents@queensu.ca Principal Investigator: Denis E O'Donnell, MD, FRCPC 收起 << |
| NCT00498251 | Lung Injury, Acute ... 展开 >> Thoracotomy Anesthesia Intensive Care, Surgical Extravascular Lung Water 收起 << | Not Applicable | Completed | - | Switzerland ... 展开 >> University Hospital of Geneva Geneva, Switzerland, CH-1211 收起 << |
| NCT01395875 | - | Completed | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.43mL 0.49mL 0.24mL |
12.13mL 2.43mL 1.21mL |
24.25mL 4.85mL 2.43mL |
| 参考文献 |
|---|
|
[1]Zhang W, et al. Eur J Pharmacol,?010, 647(1-3), 178-187. [2]Shaik N, et al. Cell Physiol Biochem,?012, 30(6), 1517-1525. |